ΒΆ LTB4
ΒΆ Definition
Leukotriene B4 (LTB4) is a potent pro-inflammatory lipid mediator synthesized from arachidonic acid via the 5-lipoxygenase pathway. It serves as the most powerful chemoattractant for neutrophils, orchestrating their recruitment, activation, and antimicrobial functions. LTB4 demonstrates context-dependent dual functionality: essential for acute pathogen clearance and tissue protection in the gut and bone, yet capable of driving chronic inflammation when production becomes excessive or prolonged.
ΒΆ Picture It
Think of LTB4 as an emergency flare gun fired from the battlefield of tissue damage. When neutrophils and other immune cells detect danger, they convert stored arachidonic acid (like gunpowder in storage) into LTB4 flares using the 5-LOX enzyme as the firing mechanism. These bright chemical flares shoot into the surrounding tissue fluid, creating a visible gradient β brightest at the injury site, dimmer further away.
Circulating neutrophils are like firefighters on patrol. They have special goggles (BLT1 and BLT2 receptors) that can see these flares from far away. The moment they spot the LTB4 signal, they drop everything, stick to the blood vessel walls, squeeze through gaps (chemotaxis), and sprint directly toward the brightest part of the flare. When they arrive, those same flares don't just guide them β they arm them, triggering the neutrophils to release toxic chemicals (degranulation) and produce tissue-damaging oxygen radicals (respiratory burst) to kill invaders.
In acute infection, this is lifesaving. The flares summon exactly the right number of firefighters for exactly the right duration. But imagine those flares never stop burning β that's chronic inflammation. Neutrophils keep arriving, keep releasing their toxic cargo, and the tissue burns from friendly fire. However, in the gut lining and bone, controlled LTB4 flares actually serve a protective role, like controlled burns preventing forest fires β they stimulate repair cell proliferation and maintain barrier integrity when properly regulated.
ΒΆ Mechanism
LTB4 synthesis begins when cellular stress, PAMPs, or DAMPs activate phospholipase A2 (PLA2G7), releasing arachidonic acid from cell membrane phospholipids:
Step-by-step cascade:
-
Arachidonic acid liberation: PLA2G7 (phospholipase A2) cleaves arachidonic acid from membrane glycerophospholipids at the sn-2 position in response to TNF-Ξ±, IL-1Ξ², C5a, or mechanical stress
-
5-LOX translocation: 5-lipoxygenase translocates from cytosol to nuclear membrane, binding to Five-Lipoxygenase-Activating Protein (FLAP) and converting arachidonic acid β 5-hydroperoxyeicosatetraenoic acid (5-HPETE)
-
LTA4 formation: 5-LOX catalyzes dehydration of 5-HPETE β leukotriene A4 (LTA4), an unstable epoxide intermediate
-
LTB4 synthesis: LTA4 hydrolase stereospecifically converts LTA4 β LTB4 (5S,12R-dihydroxy-6,14-cis-8,10-trans-eicosatetraenoic acid)
-
Receptor activation: LTB4 binds two G-protein-coupled receptors:
- BLT1 (high affinity, Kd ~1-10 nM): Primary mediator on neutrophils, monocytes, eosinophils, T cells
- BLT2 (low affinity, Kd ~20-100 nM): Broader tissue distribution, regulatory role
-
Downstream signaling: BLT1 activation triggers:
- GΞ±i protein β inhibits adenylyl cyclase β βcAMP
- GΞ²Ξ³ subunits β activate PI3K/AKT pathway β actin polymerization, chemotaxis
- MAPK/ERK1-2 β activates NF-ΞΊB β transcription of pro-inflammatory genes
- Phospholipase C activation β IP3 and DAG β calcium mobilization β degranulation
- NADPH oxidase assembly β reactive oxygen species production (respiratory burst)
-
Neutrophil recruitment cascade:
-
Tissue-protective effects (context-dependent):
- In GI epithelium: stimulates proliferation via EGFR transactivation
- In bone: osteoblast stimulation, balanced osteoclast regulation
- Low-level chronic LTB4 β maintains mucosal barrier integrity
-
Metabolic inactivation: LTB4 degraded by:
- Ο-oxidation via CYP4F enzymes β 20-OH-LTB4 β 20-COOH-LTB4 (inactive)
- Ξ²-oxidation β dinor-LTB4 metabolites
- Urinary excretion of metabolites
Threshold concentrations:
- Chemotactic activity: 10β»ΒΉβ° to 10β»βΈ M
- Maximal neutrophil activation: 10β»βΈ to 10β»β· M
- Tissue levels in acute inflammation: 10-100 ng/g tissue
- Plasma levels: normally <100 pg/mL; acute inflammation >1000 pg/mL
ΒΆ Clinical Significance
LTB4 exemplifies the temporal context-dependency principle central to evolutionary cPNI: the same molecule that saves lives in acute infection can destroy tissues in chronic disease.
Acute inflammation (protective):
- LTB4 peaks within 4-6 hours of tissue injury or infection
- Essential for neutrophil-mediated bacterial clearance (especially extracellular pathogens like Staphylococcus aureus, Streptococcus pneumoniae)
- Patients with 5-LOX deficiency show impaired bacterial killing and recurrent infections
- Part of the "old danger" initiation phase in the lipid mediator class switching model β LTB4 dominates early, then declines as specialized pro-resolving mediators (SPMs) like resolvins and lipoxins rise
Chronic inflammation (pathological):
- Persistent LTB4 elevation (>500 pg/mL plasma beyond 48-72 hours) indicates failed resolution of inflammation
- Drives neutrophil-mediated tissue damage in:
- Inflammatory bowel disease: mucosal ulceration, crypt abscesses
- COPD: airway neutrophilia, emphysema progression
- Rheumatoid arthritis: synovial neutrophil infiltration, cartilage erosion
- Psoriasis: epidermal neutrophil accumulation, plaque formation
- Atherosclerosis: plaque instability via neutrophil infiltration
Intervention implications:
-
Timing is critical: Never suppress LTB4 during acute infection (first 24-48h); support lipid mediator class switching after initial pathogen control
-
Omega-3 fatty acids: EPA and DHA compete with arachidonic acid for 5-LOX, reducing LTB4 synthesis while providing substrates for resolvins
- Target: omega-3 index >8%, omega-6:omega-3 ratio <4:1
- Clinical dose: 2-4g EPA+DHA daily for chronic inflammatory conditions
-
5-LOX pathway modulation:
-
Support resolution: Prioritize SPM precursors and cofactors to enable endogenous class switching:
- Aspirin (low-dose 75-100mg): acetylates COX-2 β aspirin-triggered lipoxins
- Vitamin D: upregulates ALX-FPR2 receptor for lipoxin signaling
- Vitamin E, Selenium: protect SPMs from oxidative degradation
-
Monitor resolution biomarkers:
- LTB4:RvD1 ratio (target <2:1 indicates successful switching)
- Neutrophil-lymphocyte ratio (target
in resolved inflammation) - Sequential measurements more informative than single values
-
Selfish immune system consideration: Chronic LTB4 elevation may represent an adaptive response to persistent low-grade PAMPs/DAMPs (e.g., gut dysbiosis, chronic stress, metabolic endotoxemia). Address root causes (barrier dysfunction, microbiome restoration, allostatic load reduction) rather than merely suppressing LTB4.
Connection to metamodels:
- Metamodel 1 (chronic inflammation): LTB4 perpetuation as failed resolution
- Metamodel 3 (metabolism): LTB4 impairs insulin signaling via JNK activation β insulin resistance
- Metamodel 5 (evolutionary mismatch): Modern omega-6 to omega-3 ratio (15-20:1 vs ancestral 1-2:1) shifts toward excessive LTB4 production
ΒΆ Key Facts
- LTB4 is 100-1000x more potent as a neutrophil chemoattractant than C5a or IL-8
- Half-life in vivo: 2-5 minutes (rapidly metabolized, preventing systemic spread)
- Peak tissue concentration in acute inflammation: 4-6 hours post-injury
- Primary cellular sources: neutrophils (80%), monocytes, epithelial cells, thrombocytes
- BLT1 receptor density: ~50,000 receptors per neutrophil
- Detectable chemotactic gradient maintained across distances up to 200 ΞΌm from source
- Normal plasma concentration: <100 pg/mL; acute inflammation: 500-5000 pg/mL
- In chronic inflammation, LTB4 levels remain 2-10x baseline for weeks to years
- Omega-6-derived LTB4 (from arachidonic acid) is 10-100x more potent than omega-3-derived LTB5
- Urinary LTB4 metabolites (LTB4-M1) serve as non-invasive biomarker of whole-body 5-LOX activity
- BLT1 knockout mice show impaired bacterial clearance but protected from asthma, atherosclerosis, and colitis
- LTB4 production capacity declines with age (30-50% reduction by age 70), potentially explaining immunosenescence
- In gut mucosa, physiological LTB4 concentrations (10β»ΒΉβ° to 10β»βΉ M) stimulate epithelial proliferation and barrier repair
ΒΆ Connections
- Leukotriene B4 β identical molecule, alternative notation convention
- arachidonic acid β direct precursor fatty acid, released by PLA2G7 from membrane phospholipids
- 5-lipoxygenase β rate-limiting enzyme catalyzing LTA4 formation from arachidonic acid
- leukotrienes β family of related eicosanoid mediators including cysteinyl leukotrienes (LTC4, LTD4, LTE4)
- neutrophils β primary cellular target and major producer of LTB4, expressing high-density BLT1 receptors
- lipid mediator class switching β LTB4 production dominates initiation phase, declines as SPMs rise during resolution
- COX-2 β competing pathway converting arachidonic acid to PGE2 and prostaglandins
- PGE2 β synergizes with LTB4 in early inflammation, then antagonizes via EP4 receptor signaling
- resolvins β specialized pro-resolving mediators that actively counter-regulate LTB4 signaling and terminate neutrophil recruitment
- lipoxins β endogenous resolution mediators that inhibit 5-LOX and block BLT1 signaling via ALX-FPR2 receptor
- C5a β complement fragment acting as secondary neutrophil chemoattractant, less potent than LTB4
- IL-8 β chemokine chemoattractant produced downstream of LTB4/BLT1 activation, amplifying recruitment
- NF-ΞΊB β transcription factor activated by BLT1 signaling, upregulating pro-inflammatory gene expression
- chronic inflammation β LTB4 overproduction is hallmark biomarker and driver of non-resolving inflammatory states
- omega-3 fatty acids β EPA and DHA competitively inhibit LTB4 synthesis while generating less inflammatory LTB5
- EPA β substrate for omega-3-derived LTB5, which is 10-100x less potent at BLT1 receptor
- inflammatory bowel disease β excessive mucosal LTB4 drives neutrophil-mediated ulceration in Crohn's disease and ulcerative colitis
- gut barrier function β physiological LTB4 supports epithelial proliferation; pathological levels cause barrier breakdown
- efferocytosis β resolution process that LTB4 overproduction blocks by sustaining neutrophil influx and preventing macrophage switching
- insulin resistance β LTB4 activates JNK pathway, phosphorylating insulin receptor substrate-1 at inhibitory sites
- metabolic syndrome β elevated plasma LTB4 correlates with visceral adiposity and systemic insulin resistance
- NADPH oxidase β enzyme complex assembled upon BLT1 activation, generating reactive oxygen species for pathogen killing
- myeloperoxidase β neutrophil enzyme released upon LTB4-triggered degranulation, producing hypochlorous acid
- atherosclerosis β LTB4 recruits neutrophils to atherosclerotic plaques, promoting rupture and thrombosis
- asthma β BLT1-mediated neutrophil accumulation contributes to severe, steroid-resistant phenotypes
ΒΆ Module References
- Module 1: Resoleomics β LTB4 as prototypical "old danger" signal in initiation phase
- Module 1: Eicosanoid Switch β temporal transition from LTB4 dominance to SPM dominance
- Module 5: Specialized Pro-Resolving Mediators β counter-regulation of LTB4 signaling by resolvins and lipoxins
- Module 5: Lipid Mediator Class Switching β LTB4 decline as biomarker of successful resolution programming